Patrys Limited (ASX:PAB)

Australia flag Australia · Delayed Price · Currency is AUD
0.0340
-0.0010 (-2.94%)
Mar 10, 2026, 3:57 PM AEST
41.67%
Market Cap 18.20M
Revenue (ttm) 100.38K
Net Income (ttm) -4.51M
Shares Out 535.37M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 912,936
Average Volume 1,023,128
Open 0.0340
Previous Close 0.0340
Day's Range 0.0310 - 0.0350
52-Week Range 0.0120 - 0.0490
Beta 0.79
RSI 46.46
Earnings Date Feb 22, 2026

About Patrys

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is base... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 10
Stock Exchange Australian Securities Exchange
Ticker Symbol PAB
Full Company Profile

Financial Performance

In fiscal year 2025, Patrys's revenue was 828,540, a decrease of -40.57% compared to the previous year's 1.39 million. Losses were -3.01 million, -14.86% less than in 2024.

Financial Statements

News

There is no news available yet.